Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-volume vs regular-volume PENG block with ropivacaine after total hip arthroplasty
ChiCTR2300077281Phase 4Completed
- Sponsor
- The Third Affiliated Hospital of Chongqing Medical University
- Start
- Aug 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of ropivacaine in hip osteoarthritis (2 arms), sponsored by The Third Affiliated Hospital of Chongqing Medical University. Primary endpoint: Dynamic VAS pain score at 6 hours postoperatively. Started Aug 2024; status: completed.
02
Drugs
ropivacaine
03
Conditions
hip osteoarthritis
Beyond the preview
Go deeper on ChiCTR2300077281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300077281.